Literature DB >> 2885408

Amphetamine-like effects of anorectics and related compounds in pigeons.

S M Evans, C E Johanson.   

Abstract

Four pigeons were trained to discriminate injections of d-amphetamine (AMPH; 2.0 mg/kg i.m.) from saline with responding maintained under a fixed-ratio 30 schedule of food delivery. When drugs used therapeutically as anorectics were tested, they consistently produced greater than 80% of AMPH-appropriate responding. The order of potency for substituting for AMPH was: mazindol greater than AMPH = phenmetrazine = phentermine greater than chlorphentermine = phendimetrazine = diethylpropion greater than clortermine = mefenorex. Other anorectics such as phenylpropanolamine (0.3-30.0 mg/kg) and fenfluramine (1.0-17.0 mg/kg) only substituted partially for AMPH whereas benzphetamine (1.0-100.0 mg/kg) resulted primarily in saline-appropriate responding. Compounds related to AMPH in biochemical mechanism of action or psychomotor stimulant activity also were tested. Methylphenidate (0.1-3.0 mg/kg), piribedil (0.3-17.0 mg/kg) and nisoxetine (0.03-1.0 mg/kg) shared discriminative stimulus properties with AMPH whereas bupropion (1.0-30.0 mg/kg) and propylhexedrine (10.0-100.0 mg/kg) substituted for AMPH in two of three pigeons tested. In contrast, caffeine and fenetylline resulted principally in saline-appropriate responding. Compounds from pharmacological classes not related to AMPH, such as morphine, diazepam and phencyclidine, failed to substitute for AMPH. In general, compounds with anorectic and/or stimulant properties shared discriminative stimulus properties with AMPH.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2885408

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Agonist replacement therapy for cocaine dependence: a translational review.

Authors:  Craig R Rush; William W Stoops
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 2.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

3.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans.

Authors:  S J Heishman; J E Henningfield
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Cocaine-like discriminative stimulus effects of phendimetrazine and phenmetrazine in rats.

Authors:  Clayton T Bauer; S Stevens Negus; Bruce E Blough; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

Review 6.  Drug discrimination by humans compared to nonhumans: current status and future directions.

Authors:  J B Kamien; W K Bickel; J R Hughes; S T Higgins; B J Smith
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 7.  Norepinephrine and stimulant addiction.

Authors:  Mehmet Sofuoglu; R Andrew Sewell
Journal:  Addict Biol       Date:  2008-09-22       Impact factor: 4.280

8.  Role of phenmetrazine as an active metabolite of phendimetrazine: evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys.

Authors:  Matthew L Banks; Bruce E Blough; Timothy R Fennell; Rodney W Snyder; S Stevens Negus
Journal:  Drug Alcohol Depend       Date:  2012-12-01       Impact factor: 4.492

9.  Safety and tolerability of intranasal cocaine during phendimetrazine maintenance.

Authors:  William W Stoops; Justin C Strickland; Lon R Hays; Abner O Rayapati; Joshua A Lile; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2016-03-01       Impact factor: 4.530

10.  Abuse Potential of Oral Phendimetrazine in Cocaine-dependent Individuals: Implications for Agonist-like Replacement Therapy.

Authors:  B Levi Bolin; William W Stoops; Jeremy P Sites; Craig R Rush
Journal:  J Addict Med       Date:  2016 May-Jun       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.